Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553992 | 1.00 | MMP12 (0.54) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL3341734 | 0.98 | MMP12 (0.53) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL26109837 | 0.91 | CNR2 (0.53) | CNR2PTPN1MEN1KMT2AHDAC8 | |
| SCHEMBL26109839 | 0.91 | CNR2 (0.53) | CNR2PTPN1MEN1KMT2AHDAC8 | |
| SCHEMBL27694707 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL6567538 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL6567542 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL20549139 | 0.87 | CNR2 (0.49) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL31499163 | 0.87 | NAALAD2 (0.58) | MMP2CNR2NAALAD2MEN1KMT2A | |
| SCHEMBL3341731 | 0.87 | CNR2 (0.49) | MMP12MMP2MMP8MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035425-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | BURZYNSKI STANISLAW R (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230190694-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | BURZYNSKI STANISLAW R (US) | 2023-06-22 | — | — | US | disclosed |
| US-11344521-B2 | Methods for the treatment of leptomeningeal disease | BURZYNSKI, STANISLAW R. | 2022-05-31 | — | — | US | disclosed |
| US-20220151968-A1 | METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | BURZYNSKI STANISLAW R (US) | 2022-05-19 | — | — | US | disclosed |
| US-11234951-B2 | Methods for the treatment of glioblastoma multiforme | BURZYNSKI STANISLAW R (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210145776-A1 | METHODS FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE | BURZYNSKI, STANISLAW R. | 2021-05-20 | — | — | US | disclosed |
| US-20210038552-A1 | METHODS FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE | BURZYNSKI, STANISLAW R. | 2021-02-11 | — | — | US | disclosed |
| US-20200345674-A1 | METHODS FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA (RGBM) | BURZYNSKI STANISLAW R (US) | 2020-11-05 | — | — | US | disclosed |
| US-10624869-B2 | Methods for the treatment of recurrent glioblastoma (RGBM) | BURZYNSKI STANISLAW R (US) | 2020-04-21 | — | — | US | disclosed |
| EP-1855665-B1 | USE OF PHENYLACETYL-DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VON HIPPEL-LINDAU (VHL) DISEASE | BURZYNSKI STANISLAW R (US) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145776-A1 | METHODS FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE | CLN6, GALC, GBA1 | MMP12 269/4885MMP2 635/4885MMP8 486/4885 |
| US-11234951-B2 | Methods for the treatment of glioblastoma multiforme | IDH3B, IDH1, IDH2 | MMP12 1465/4885MMP2 2653/4885MMP8 3219/4885 |
| US-20230190694-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | TP53, DNASE1L3, RNASE1 | MMP12 1234/4885MMP2 786/4885MMP8 39/4885 |
| US-10624869-B2 | Methods for the treatment of recurrent glioblastoma (RGBM) | IDH3B, IDH1, IDH2 | MMP12 1422/4885MMP2 2351/4885MMP8 3013/4885 |
| US-20200345674-A1 | METHODS FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA (RGBM) | IDH3B, IDH1, IDH2 | MMP12 1422/4885MMP2 2351/4885MMP8 3013/4885 |
| US-11344521-B2 | Methods for the treatment of leptomeningeal disease | CLN6, GALC, GBA1 | MMP12 269/4885MMP2 635/4885MMP8 486/4885 |
| US-20220151968-A1 | METHODS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | IDH3B, IDH1, IDH2 | MMP12 1465/4885MMP2 2653/4885MMP8 3219/4885 |
| US-20210038552-A1 | METHODS FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE | CLN6, GALC, GBA1 | MMP12 269/4885MMP2 635/4885MMP8 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.